glp-1 receptor agonists in idiopathic intracranial hypertension and the Challenge of Weight Loss glp 1 receptor agonists in

L-glutathione is a sulfur tripeptide composed of 3 amino acids: glutamic acid, cysteine and glycine

peripheral nerve motor or sensory loss, Guillaine Barre type syndrome, multiple cranial nerve palsies Immune related adverse events (IrAE) occur in up to 90% patients administered ipilimumab up to 70% patients administered PD1/PDL1 inhibitors (pembrolizumab, nivolumab, atezolizumab) First line pembrolizumab (PD1) in lung cancer 1 in 10 had a G3 or G4 toxicity (better than chemotherapy) 1 in 20 stopped treatment due to toxicity These are very rarely immunosuppressive drugs sick patients are unlikely to have neutropenic sepsis mainstay of treatment of immune related adverse events - STEROIDS Immune Related Adverse Events: Primary care need to be aware that side effects may not be immediate: onset of these toxicities varies but usually starts within the first 8 to 12 weeks of initiation of treatment Reference: Brooks M, Olsson-Brown A

503B Pharmacies 503A Pharmacies compound medications for specific patients based on individual prescriptions

The alkylation of selenocysteine directly inactivates GPX4 and induces lipid peroxidation, thereby inducing ROS production [23, 150, 160]